Altimmune Inc
(NAS:ALT)
$
6.94
0.18 (2.66%)
Market Cap: 493.23 Mil
Enterprise Value: 330.19 Mil
PE Ratio: 0
PB Ratio: 3.23
GF Score: 36/100 Altimmune Inc (ALT) Transcripts
- Q4 2023 Altimmune Inc Earnings Call TranscriptMar 27, 2024$8.89 (+2.77%)Earnings
- Altimmune Inc Conference Call TranscriptDec 01, 2023
- Q3 2023 Altimmune Inc Earnings Call TranscriptNov 07, 2023$2.7 (+1.12%)Earnings
- Altimmune Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Altimmune Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q2 2023 Altimmune Inc Earnings Call TranscriptAug 10, 2023$3.04 (+3.05%)Earnings
- Altimmune Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Altimmune Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q1 2023 Altimmune Inc Earnings Call TranscriptMay 11, 2023$5.33 (+7.03%)Earnings
- Altimmune Inc Conference Call TranscriptMar 21, 2023
- Q4 2022 Altimmune Inc Earnings Call TranscriptFeb 28, 2023$12.59 (+6.42%)Earnings
- Altimmune Inc Topline Results of Pemvidutide in Subjects with NAFLD Call TranscriptDec 20, 2022
- Altimmune Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Q3 2022 Altimmune Inc Earnings Call TranscriptNov 10, 2022$10.58 (+9.18%)Earnings
- Altimmune Inc at H C Wainwright Hepatitis B Virus (HBV) Virtual Conference TranscriptOct 18, 2022
- Altimmune Inc Conference Call TranscriptSep 14, 2022
- Q2 2022 Altimmune Inc Earnings Call TranscriptAug 11, 2022$13.77 (+7.08%)Earnings
- Altimmune Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Altimmune Inc Earnings Call TranscriptMay 12, 2022$4.28 (+8.63%)Earnings
- Q4 2021 Altimmune Inc Earnings Call TranscriptMar 15, 2022$5.9 (-8.24%)Earnings
- Q3 2021 Altimmune Inc Earnings Call TranscriptNov 10, 2021$10.92Earnings
- Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 12, 2021
- Altimmune Inc to Host Key Opinion Leader Call on Pemvidutide Phase 1 Clinical Trial Results - Conference Call TranscriptSep 30, 2021
- Altimmune Inc to Discuss the 12-Week Data from Phase 1 Clinical Trial of ALT-801 - Conference Call TranscriptSep 28, 2021
- Q2 2021 Altimmune Inc Earnings Call TranscriptAug 11, 2021$11.15 (+2.48%)Earnings
- Altimmune Inc Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers Conference Call TranscriptJun 16, 2021
- Q1 2021 Altimmune Inc Earnings Call TranscriptMay 17, 2021$14.18 (+5.98%)Earnings
- Altimmune Inc to Present AdCOVIDâ„¢ intranasal COVID-19 at the World Vaccine Congress TranscriptMay 04, 2021
- Q4 2020 Altimmune Inc Earnings Call TranscriptFeb 25, 2021$17.2 (-12.16%)Earnings
- Q3 2020 Altimmune Inc Earnings Call TranscriptNov 10, 2020$9.33 (+19.08%)Earnings
- Altimmune Inc Annual Shareholders Meeting TranscriptSep 24, 2020
- Q2 2020 Altimmune Inc Earnings Call TranscriptAug 12, 2020$22.58 (-2.25%)Earnings
- Altimmune Inc Acceptance of IND for Covid-19 Therapeutic Testing - Call TranscriptJun 01, 2020
- Q1 2020 Altimmune Inc Earnings Call TranscriptMay 14, 2020$4.49 (+8.72%)Earnings
- Q4 2019 Altimmune Inc Earnings Call TranscriptMar 27, 2020$2.85 (-12.31%)Earnings
- Q2 2019 Altimmune Inc Earnings Call TranscriptAug 14, 2019$2.03 (-4.25%)Earnings
- 1